Cost-effectiveness analysis of hepatitis A vaccination strategies for adults

Hepatology

Volumn 30, Issue 4, 1999, Pages 1077-1081

  Barry O'Connor, J ^a   Imperiale, Thomas F ^b   Singer, Mendel E ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEPATITIS A; HUMAN; INFECTION PREVENTION; MODEL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; VACCINATION;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEPATITIS A; HEPATITIS ANTIBODIES; HEPATOVIRUS; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UNITED STATES; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 20644463199     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300422     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention; hepatitis surveillance 1996;56:16-18.
2. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins, 1991;14-20.
3. Second National Health and Nutrition Examination Survey (NHANES II); 1976-80.
4. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. 1996;45:15.
5. Tong MJ, Neveen S, El-Farra, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. Journal of Infectious Dis 1995;171(Suppl1):15S-18S.
6. Innis BL, Snitbahn R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:28-34.
7. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, et al. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Eng J Med 1992;327:453-457.
8. Wiens B, Bohidar N, Pigeon J, Egan J, Hurni W, Brown L, Kuter BJ, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996;49:235-241.
9. VanDamme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994;44:446-451.
10. Van Doorslaer E, Tormans G, van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travelers. J Med Virol 1994;44:463-469.
11. Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infectious Agents and Disease 1994;1:38-49.
12. Tormans G, VanDamme P, VanDoorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travelers. Vaccine 1992;10(Suppl1):88S-92S.
13. Tormans G, van Damme P, van Doorslaer E. A cost-effectiveness analysis of indications for prevention of hepatitis A in travelers. J Travel Med 1994;1(3):127-135.
14. Behrens RH, Roberts JA. Is travel prophylaxis worthwhile? Economic appraisal of prophylactic measures against malaria, hepatitis A and typhoid in travelers. BMJ 1994;309:918-922.
15. Severo CA, Fagnani F, Lafuma A. Cost-effectiveness of hepatitis A prevention in France. Pharmacoeconomics 1995;8(1):46-61.
16. Jefferson TO, Behrens RH, Demecheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 1994; 12(15):1379-1383.
17. Jefferson TO, Demicheli V, Wright D. An economic evaluation of the introduction of vaccination against hepatitis A in a peacekeeping operation: the case of the United Nations Protection Force in Yugoslavia. Int J Technol Assess Health Care 1994;10(3):490-497.
18. Das Ananya. An Economic Analysis of Different Strategies of Immunization Against Hepatitis A Virus in Developed Countries. HEPATOLOGY 1999;29:548-552.
19. Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS. Epidemiology of hepatitis A: sero-epidemiology and risk groups in the USA. Vaccine 1992 10(Suppl1);59S.
20. Morbidity and Mortality Weekly Report (MMWR) 1993;41(55):32. Centers for Disease Control and Prevention. Summary of notifiable diseases.
21. Koff R. Sero-epidemiology of hepatitis A in the United States. Journal of Infectious Diseases 1995;171(Suppl1):19S-23S.
22. Tabor E. Clinical presentation of hepatitis A. In: Gerty, RJ, ed. Hepatitis A. Academic Press, Orlando 1984, pp. 47-53.
23. Hadler SC, Purcell RH. The prospects for immunizing against hepatitis A virus. In: New Vaccine Development Vol 1, National Academic Press, Washington, 1985;252-260.
24. Hadler SC, McFarland L. Hepatitis in day care centers: Epidemiology and Prevention. Rev Infect Dis 1986;8:548-557.
25. Bader TF. Hepatitis A Vaccine. Am J Gastroenterol 1996;91(2):217-222.
26. Wiederman G, Amrosch F, Andre FE et al. Persistence of vaccine induced antibody to hepatitis A virus. Vaccine 1992; 10(Suppl1):129S-131S.
27. Drug Topics. Red Book 1997. Medical Economics Company Inc, New Jersey.
28. United States Bureau of Labor Statistics. www.bls.gov/eag.table.html. Site accessed 1997.
29. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276(15):1253-1258.